Mavorixafor - X4 Pharmaceuticals
Alternative Names: ABSK-081; AMD-070; AMD-11070; X4P 001 RD; X4P-001; X4P-001-IO; XOLREMDILatest Information Update: 04 Jul 2024
At a glance
- Originator AnorMED
- Developer Abbisko Therapeutics; X4 Pharmaceuticals
- Class Antineoplastics; Antiretrovirals; Benzimidazoles; Diamines; Hydroquinones; Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered WHIM syndrome
- Phase III Neutropenia
- Phase I/II Triple negative breast cancer
- Discontinued HIV-1 infections; Malignant melanoma; Renal cell carcinoma; Solid tumours; Waldenstrom's macroglobulinaemia
Most Recent Events
- 27 Jun 2024 Phase-III clinical trials in Neutropenia (In adolescents, In adults, In the elderly) in Georgia (PO) (NCT06056297)
- 27 Jun 2024 Adverse events and efficacay data from a phase I/II trial in Chronic neutropenia released by X4 Pharmaceuticals
- 07 May 2024 X4 Pharmaceuticals announces intention to submit regulatory application to European Medicines Agency (EMA) for WHIM syndrome in late 2024 or early 2025